Amdocs price target lowered to $85 from $100 at Baird

Baird lowered the firm’s price target on Amdocs to $85 from $100 and keeps a Neutral rating on the shares. The firm said the company’s initial 2024 revenue guidance missed prior expectations, with half of the growth also from recent acquisitions, implying even weaker organic trends.